

Publikationen

Privat-Dozent Dr. med. Andreas Eisenhardt

11. [Failure to attend appointments: data analysis of a urological group practice over 12 months.](#)

Eisenhardt A, Schneider B, Schneider T, Rossi R, Schenck M.
Urologe A. 2012 Aug;51(8):1095-1098

12. [Central venous port implantations via the cephalic vein applying an intravasal electrographic control of the catheter tip position: a single-center experience of 316 cases.](#)

Schenck M, Schneider T, Rübben H, Eisenhardt A.
World J Urol. 2012 Jun;30(3):399-404

13. [Genotype of the GNB3 C825T polymorphism, A risk factor for the development and course of prostate cancer?](#)

Eisenhardt A, Scherag A, Kempin M, Jöckel KH, Rübben H.
Urologe A. 2011 Sep;50(9):1137-1142

14. [Lack of association of the genotype in the GNAS Fok I polymorphism and prostate cancer.](#)

Eisenhardt A, Scherag A, Jöckel KH, Reis H, Rübben H, Siffert W.
Urol Int. 2011;87(1):80-86

15. [Regulatory BCL2 promoter polymorphism \(-938C>A\) is associated with adverse outcome in patients with prostate carcinoma.](#)

Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nückel H, Eisenhardt A, Rübben H, Schmid KW, Siffert W, Eggert A, Schramm A, Schulte JH.
Int J Cancer. 2011 Nov 15;129(10):2390-2399

16. Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population.

Eisenhardt A, Stief C, Porst H, Wetterauer U, Weidner W, Rübben H, Sperling H.
Andrologia. 2010 Aug;42(4):218-224

17. The prognostic value of cadherin switch in bladder cancer.

Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S, Szarvas T.

Oncol Rep. 2010 Apr;23(4):1125-32.

18. Practice marketing. Data analysis of a urological group practice.

Schneider T, Schneider B, Eisenhardt A, Sperling H.
Urologe A. 2009 Jul;48(7):785-789

19. Single base polymorphisms and erectile dysfunction.

Eisenhardt A, Rübben H, Sperling H.
Urologe A. 2008 Dec;47(12):1579-1581

20. Characterization of intron-1 haplotypes of the G protein beta 4 subunit gene--association with survival and progression in patients with urothelial bladder carcinoma.

Riemann K, Struwe H, Eisenhardt A, Obermaier B, Schmid KW, Siffert W. Pharmacogenet Genomics. 2008 Nov;18(11):999-1008

21. Infections of the genitourinary tract and refertilisation operations.

Eisenhardt A, Sperling H.

Andrologia. 2008 Apr;40(2):97-99

22. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer.

Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W. Int J Clin Pharmacol Ther. 2007 Aug;45(8):423-430

23. Does cigarette smoking influence the survival of patients with prostate cancer?.

Jäger T, Eisenhardt A, Rübben H, Lümmen G.

Urologe A. 2007 Apr;46(4):397-400

24. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

Frey UH, Lümmen G, Jäger T, Jöckel KH, Schmid KW, Rübben H, Müller N, Siffert W, Eisenhardt A.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):759-763

25. Therapy for infertile couples.

Sperling H, Eisenhardt A, Becker M, Rübben H.

Urologe A. 2005 Oct;44(10):1147-1153

26. Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer.

Eisenhardt A, Siffert W, Rosskopf D, Musch M, Mosters M, Roggenbuck U, Jöckel KH, Rübben H, Lümmen G.

World J Urol. 2005 Sep;23(4):279-286

27. Molecular biology approach to explain lymphatic metastasis.

Vom Dorp F, Wullich B, Gulbins E, Eisenhardt A.

Urologe A. 2005 Jun;44(6):608-13

28. Quantification of G protein Gaalphas subunit splice variants in different human tissues and cells using pyrosequencing.

Frey UH, Nückel H, Dobrev D, Manthey I, Sandalcioglu IE, Eisenhardt A, Worm K, Hauner H, Siffert W.

Gene Expr. 2005;12(2):69-81

29. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

Frey UH, Eisenhardt A, Lümmen G, Rübben H, Jöckel KH, Schmid KW, Siffert W.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):871-877

30. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer.
Eisenhardt A, Frey U, Tack M, Rosskopf D, Lümmen G, Rübben H, Siffert W.
Eur Urol. 2005 Jan;47(1):111-117
31. Inhaled immunotherapy for pulmonary metastases of renal cell cancer.
Lümmen G, Schenck M, Börgermann C, Eisenhardt A, Vom Dorp F, Sperling H, Rübben H.
Urologe A. 2004 Apr;43(4):457-461
32. Biochips in bladder cancer research.
Suhr J, Eisenhardt A, Schmid KW, vom Dorp F, Otto T.
Urologe A. 2003 Jul;42(7):927-932
33. ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.
Eisenhardt A, Sperling H, Hauck E, Porst H, Stief C, Rübben H, Müller N, Siffert W.
Urology. 2003 Jul;62(1):152-157
34. Genetic risk factors for erectile dysfunction and genetic determinants of drug response--on the way to improve drug safety?
Eisenhardt A, Siffert W.
Herz. 2003 Jun;28(4):304-313
35. Occurrence, diagnostics and therapeutic management of hydronephrosis in pediatric patients in Germany.
Eisenhardt A, Arntzen D, Conrad S, Westenfelder W, Sperling H, Hoyer PF, Rübben H.
Urologe A. 2003 Apr;42(4):538-546
36. [Characterization of the splice variant Gbeta3v of the human G-protein Gbeta3 subunit.](#)
Rosskopf D, Kielbik M, Manthey I, Bilmen G, Eisenhardt A, Siffert W.
Biochim Biophys Acta. 2003 Apr 15;1626(1-3):33-42
37. [Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study.](#)
Sperling H, Eisenhardt A, Virchow S, Hauck E, Lenk S, Porst H, Stief C, Wetterauer U, Rubben H, Muller N, Siffert W.
J Urol. 2003 Mar;169(3):1048-1051
38. [Identification and characterization of G beta 3s2, a novel splice variant of the G-protein beta 3 subunit.](#)
Rosskopf D, Manthey I, Habich C, Kielbik M, Eisenhardt A, Nikula C, Urban M, Kohnen S, Graf E, Ravens U, Siffert W.
Biochem J. 2003 Apr 1;371(Pt 1):223-232
39. [Influence of pertussis toxin on superficial bladder carcinoma in rats.](#)
Lümmen G, Sperling H, Eisenhardt A, vom Dorp F, Otto T, Rübben H.
Urol Res. 2002 Jul;30(3):199-203

Stand März 2016